RedHill Biopharma Ltd. Provides Update on Planned NDA Filing for RHB-102 (Once Daily Anti-Emetic) in Q1 2014 and Commences PK Program

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TEL-AVIV, Israel, July 11, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, patent-protected, new formulations and combinations of existing drugs, reported that it had commenced dosing in the first of two supplementary pharmacokinetic studies with RHB-102, a patent protected, oral, extended-release (24 hours) formulation of ondansetron. Ondansetron is the active ingredient in GlaxoSmithKline's ZofranĀ® immediate release tablets for the prevention of radiotherapy induced nausea and vomiting (RINV) and chemotherapy induced nausea and vomiting (CINV).

Help employers find you! Check out all the jobs and post your resume.

Back to news